Male and female enrolled patients must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study. Corticosteroids : Patients requiring an increase in corticosteroids, with the exception of nasal or inhaled steroid, such that at the time of first vaccination they require a dose above physiologic levels, may remain in the study but will be replaced for assessment of safety as increased Re-MATC H Protocol Page 49 of 106 Version: 20180628 steroid usage may mask risks of autoimmune toxicity. For the purposes of this study, physiologic dose will be defined as < 4 mg of dexamethasone/day. Medical Conditions : Patients with the following conditions will be excluded to avoid confounding results: • Patients with an active infection requiring treatment or an unexplained febrile (>101.5o F) illness. • Patients with known immunosuppressive disease , human immunodeficiency virus infection , or carriers of Hepatitis B or Hepatitis C virus . • Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease. • Patients receiving concomitant medications that may interfere with study outcome (e.g., immunosuppressive agents). • Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) that would compromise the patient’s ability to tolerate protocol therapy or would likely interfere with the study procedures or results. Patients with the inability to return for follow -up visits or obtain follow -up studies required to assess toxicity to therapy 10.3 Inclusion of Women and Minorities Our br ain tumor studies are open to patients of all ages, both sexes, and all minorities. In addition, certain diseases that we treat occur preferentially in one gender or minority than another. For example, carcinoma of the breast is a frequent cause of metas tatic brain tumors and, of course, is much more common in women than in men. Although the lung cancer incidence is rising in women, the incidence is still higher in men and it is also a frequent cause of metastatic brain tumors. Primary brain tumors and metastatic brain tumors from some very common tumors such as melanoma are an infrequent disease in African -American populations. Our accrual statistics reflect the lower incidence in the African -American population. We will continue to actively recruit women and minorities into this study using methods that have shown previous success in recruiting the participation of these subgroups. We routinely send letters to our primary referring physicians notifying them of our interest in including minorities and women in all our brain tumor clinical trials. 11. DESCRIPTION OF THE R ECRUITMENT PROCESS 11.1 Recruitment The following table shows the incidence rates by ICCC group and race/ethnicity for both sexes, 1992- 1999 as provided by the Central Brain Tumor Registry of t he United States. A breakdown by sex was not available but the observation has been that in all race/ethnicity groups the incidence is slightly higher in males. *SEER Cancer Incidence Public -Use Data, 1992 -1999. Number per 1,000,000 WHITE 28.7 AFRICAN AMERICAN 24.1 NATIVE AMERICAN/ALASKA NATIVE 14.1 ASIAN/PAC ISLANDER 22.0 HISPANIC 21.7 Re-MATC H Protocol Page 50 of 106 Version: 20180628 Our demographics of all brain tumor patients treated at the Preston A. Wells, Jr., Center for Brain Tumor Therapy at the University of Florida does not differ significantly from the demographic break down of brain tumor incidences nationwide, demonstrating that a representative spectrum of patients affected by this disease are routinely seen at our Center . 11.2 Screening and Enrollment Potentially e ligible patients with reMB/PNET scheduled to undergo definitive surgical resection will be identified through direct referral to the multi- institutional sites . In select cases, patients at outside institutions who have had surgical resection and tumor tis sue snap frozen and available for TTRNA will be consider for enrollment. PHI will be reviewed by the PI(s) and/or Study Coordinator but not recorded in order to pre -screen patients for eligibility for this trial. The pre -screening PHI will consist of a r eview of the medical record to confirm presentation of first recurrence of an initial diagnosis of MB or central PNET after receipt of previous definitive focal +/ - craniospinal irradiation for diagnosis of MB/PNET in patients < 30 years of age at time of enrollment. Of note, patients with recurrent MB/PNET who have failed prior radiation therapy or are not able to receive radiation therapy due to genetic disorders that put them at significant risk for radiation -induced secondary malignancies (ie. Gorlin’s syndrome or NF1 mutation) will still be eligible to receive treatment The guardian(s) of pediatric patients or young adult patients potentially eligible for this trial will be approached by PI(s) and/ or Study Coordinator about interest in the study and to give informed consent to participation in this clinical trial. At the time of consent the PI(s) of the various treatment teams will be available to answer questions and provide any clarification needed regarding the content of th e consent document or clinical study details. The Study Coordinator will also be present to obtain informed consent and provide a copy of the signed documentation to the guardian or adult patient. Given the history of safety for immunotherapy in adult p atients we don’t anticipate significant toxicity with this treatment regimen. A ll patients enrolled on the study, even if taken off study prior to treatment, will be included in the data analysis on an intent to treat basis. We anticipate that a minimum of 80% of patients enrolled will proceed to HDC + PBSCT and receive DC + xALT therapy without prior tumor progression and therefore anticipate targeted enrollment using multi- institutional study sites . The target distribution for patients that will be treated with DC + xALT therapy based on the SEER Cancer Incidence Public- Use Data is shown in the following Table: Phase I Patient Numbers White African - American Hispanic Asian Other Male Female Male Female Male Female Male Female Male Female 9 4 3 1 0 0 0 0 0 1 0 Phase II 35 17 12 1 1 1 0 0 1 1 1 TOTAL 44 21 15 2 1 1 0 0 1 2 1 Actual accrual will be actively reviewed by the PI (Dr. Duane A.